These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Abnormal alanine aminotransferase level in blood units from donors in Montreal does not indicate high risk of transmitting hepatitis. Steinbrecher UP; Kovacs TO; Gelly A; Tourigny M Clin Invest Med; 1983; 6(4):327-30. PubMed ID: 6671363 [TBL] [Abstract][Full Text] [Related]
5. Strategies for the prevention of post-transfusion hepatitis. Mintz PD Ann Clin Lab Sci; 1984; 14(3):198-207. PubMed ID: 6428295 [TBL] [Abstract][Full Text] [Related]
6. Post-transfusion hepatitis. Sudden drop of its incidence associated with hyperbilirubinemic donors disqualification. Pintera J; Krácmar C; Pinterová A Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(3):415-25. PubMed ID: 2428716 [TBL] [Abstract][Full Text] [Related]
7. Markers for transfusion-associated hepatitis in north Indian blood donors: prevalence and trends. Singh B; Verma M; Verma K Jpn J Infect Dis; 2004 Apr; 57(2):49-51. PubMed ID: 15118208 [TBL] [Abstract][Full Text] [Related]
8. Prevalence of antibodies to hepatitis E virus among Japanese blood donors: identification of three blood donors infected with a genotype 3 hepatitis E virus. Fukuda S; Sunaga J; Saito N; Fujimura K; Itoh Y; Sasaki M; Tsuda F; Takahashi M; Nishizawa T; Okamoto H J Med Virol; 2004 Aug; 73(4):554-61. PubMed ID: 15221899 [TBL] [Abstract][Full Text] [Related]
9. Controlling post-transfusion hepatitis: a proposal to publicize hepatitis rates of transfusion facilities. Finkelstein SN; Sapolsky HM Am J Law Med; 1979; 5(1):1-9. PubMed ID: 495608 [TBL] [Abstract][Full Text] [Related]
10. Determination of alanine aminotransferase in blood donor screening--evidence of its usefulness in the prevention of post-transfusion hepatitis. Khouri ST; Lopes EP; Perez RM; Figueiredo VM; Lanzoni VP; Silva AE; Ferraz ML Clin Lab; 2004; 50(5-6):291-4. PubMed ID: 15209437 [TBL] [Abstract][Full Text] [Related]
11. Ongoing subclinical infection of hepatitis E virus among blood donors with an elevated alanine aminotransferase level in Japan. Gotanda Y; Iwata A; Ohnuma H; Yoshikawa A; Mizoguchi H; Endo K; Takahashi M; Okamoto H J Med Virol; 2007 Jun; 79(6):734-42. PubMed ID: 17457924 [TBL] [Abstract][Full Text] [Related]
12. A nationwide survey for hepatitis E virus prevalence in Japanese blood donors with elevated alanine aminotransferase. Sakata H; Matsubayashi K; Takeda H; Sato S; Kato T; Hino S; Tadokoro K; Ikeda H Transfusion; 2008 Dec; 48(12):2568-76. PubMed ID: 18774966 [TBL] [Abstract][Full Text] [Related]
13. Epidemiological and clinical aspects of hepatitis G virus infection in blood donors and immunocompromised recipients of HGV-contaminated blood. Heuft HG; Berg T; Schreier E; Künkel U; Tacke M; Schwella N; Hopf U; Salama A; Huhn D Vox Sang; 1998; 74(3):161-7. PubMed ID: 9595643 [TBL] [Abstract][Full Text] [Related]
14. [Post-transfusion hepatitis]. Frey-Wettstein M Schweiz Med Wochenschr Suppl; 1980; (10):1-40. PubMed ID: 6769160 [No Abstract] [Full Text] [Related]
15. Prevalence, persistence and liver enzyme levels of HGV RNA-positive blood donors determined by large-scale screening and transmission by blood components. Hitzler WE; Runkel S Clin Lab; 2004; 50(1-2):25-31. PubMed ID: 15000218 [TBL] [Abstract][Full Text] [Related]
16. [State of post-transfusion hepatitis in the National Utano Sanatorium with special reference to the comparison of blood from paid donors and volunteer donors]. Ichitani M; Kusama I; Yoshida N; Kurata M; Kai T Naika; 1968 Mar; 21(3):549-52. PubMed ID: 5685637 [No Abstract] [Full Text] [Related]
17. Prevalence of TT virus infection in blood donors with elevated ALT in the absence of known hepatitis markers. Cleavinger PJ; Persing DH; Li H; Moore SB; Charlton MR; Sievers C; Therneau TM; Zein NN Am J Gastroenterol; 2000 Mar; 95(3):772-6. PubMed ID: 10710073 [TBL] [Abstract][Full Text] [Related]
18. Hepatitis B vaccination of blood donors--a cost-benefit analysis. Gesemann M; Gentner P; Scheiermann N Beitr Infusionsther Transfusionsmed; 1994; 32():110-2. PubMed ID: 9422105 [TBL] [Abstract][Full Text] [Related]
19. Based on your analysis of the benefits and costs of routine donor screening for ALT-GPT to reduce the incidence of post-transfusion non-A, non-B hepatitis in your blood services region, what action would you recommend on this matter? Vox Sang; 1983; 44(1):48-64. PubMed ID: 6402857 [No Abstract] [Full Text] [Related]